Deargen applied patent for a novel target compound candidate.
Read More
Deargen-Samsung Medical Center signed a joint research agreement using ‘AI for The Development of Alzheimer Treatment’
Deargen collaboration with Samsung Seoul Hospital, to discover new Alzheimer’s treatments using AI technology.
Read More
Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
At ACM CHIL 2021, Deargen presented study results on a model of simultaneously optimizing multiple properties of molecules.
Read More
Deargen, Nominated as TOP10 for bioanalytical service company
Deargen: Laveraging AI to Accelerate New Drug Development.
Read More
Deargen-Uppthera, co-development of Proteolytic drugs
Deargen and Uptera selected two target proteins, including anti-cancer drugs, and signed a joint research contract.
Read More
AI-based Drug Discovery, What would be the limitation?
AI-based Drug Discovery, What would be the limitation?
Read More
Handok- Signed a new drug development contract using artificial intelligence of Deargen
HANDOK and Deargen will conduct joint researches on “oncology” and other diseases using DearDTI.
Read More
Daewoong Pharmaceutical subsidiary IN Therapeutics, now developing Hearing Loss Treatment
Deargen collaboration with IN Therapeutics collaboration to develop a treatment for hearing loss.
Read More
[Press Release] Deargen- SK Chemicals- Joint research on new drug development using AI of Deargen
SKChemical and Deargen will conduct joint researches on “drug repositioning” and “de novo drug design.”
Read More
Deargen to attract 3 billion won for pre series A, recruited CBO Youngchul Bae
Deargen to attract 3 billion won for pre series A, recruited CBO Youngchul Bae
Read More